$MTEM
Molecular Templates, Inc.

2015 Q3 Form 10-Q Financial Statement

#000156459015009044 Filed on November 02, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2014 Q3 2013 Q4
Revenue $3.680M $3.680M $3.210M
YoY Change 0.0% 15.72% 58.91%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.370M $2.410M $2.450M
YoY Change -1.66% 17.56% 32.43%
% of Gross Profit
Research & Development $8.081M $8.906M $8.530M
YoY Change -9.26% 40.25% 38.47%
% of Gross Profit
Depreciation & Amortization $250.0K $300.0K $420.0K
YoY Change -16.67% -30.23% 23.53%
% of Gross Profit
Operating Expenses $10.45M $8.906M $10.99M
YoY Change 17.37% 6.01% 37.2%
Operating Profit
YoY Change
Interest Expense $30.00K $30.00K $30.00K
YoY Change 0.0% -11.76% 0.0%
% of Operating Profit
Other Income/Expense, Net $320.0K -$340.0K $230.0K
YoY Change -194.12% -105.33% -99.33%
Pretax Income -$6.430M -$7.947M -$7.510M
YoY Change -19.09% -766.14% -126.45%
Income Tax $0.00 -$202.0K $80.00K
% Of Pretax Income
Net Earnings -$6.431M -$7.745M -$7.589M
YoY Change -16.97% -758.59% -126.73%
Net Earnings / Revenue -174.76% -210.46% -236.42%
Basic Earnings Per Share -$0.09 -$0.13 -$0.13
Diluted Earnings Per Share -$0.09 -$0.15 -$0.13
COMMON SHARES
Basic Shares Outstanding 71.38M 59.85M 59.22M shares
Diluted Shares Outstanding 71.38M 61.49M

Balance Sheet

Concept 2015 Q3 2014 Q3 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.40M $67.70M $65.70M
YoY Change -16.69% -26.33% -7.2%
Cash & Equivalents $13.70M $11.20M $7.279M
Short-Term Investments $42.70M $56.50M $58.40M
Other Short-Term Assets $1.800M $1.900M $2.200M
YoY Change -5.26% 5.56% 83.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $62.20M $74.10M $86.01M
YoY Change -16.06% -25.36% -1.87%
LONG-TERM ASSETS
Property, Plant & Equipment $400.0K $600.0K $686.0K
YoY Change -33.33% -15.25% -15.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $800.0K $16.40M
YoY Change
Other Assets $1.300M $1.200M $1.059M
YoY Change 8.33% 13.31% 0.0%
Total Long-Term Assets $1.800M $2.600M $18.11M
YoY Change -30.77% 47.14% 867.88%
TOTAL ASSETS
Total Short-Term Assets $62.20M $74.10M $86.01M
Total Long-Term Assets $1.800M $2.600M $18.11M
Total Assets $64.00M $76.70M $104.1M
YoY Change -16.56% -24.09% 16.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $400.0K $3.400M $1.689M
YoY Change -88.24% 147.27% 86.01%
Accrued Expenses $9.100M $6.800M $3.161M
YoY Change 33.82% 173.2% 40.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.30M $25.00M $27.02M
YoY Change -2.8% 0.49% 54.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $70.60M $72.70M $100.6M
YoY Change -2.89% -22.41% 17.11%
Total Long-Term Liabilities $70.60M $72.70M $100.6M
YoY Change -2.89% -22.41% 17.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.30M $25.00M $27.02M
Total Long-Term Liabilities $70.60M $72.70M $100.6M
Total Liabilities $94.90M $97.70M $127.6M
YoY Change -2.87% -17.58% 23.43%
SHAREHOLDERS EQUITY
Retained Earnings -$351.7M
YoY Change 8.79%
Common Stock $328.2M
YoY Change 6.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$30.90M -$21.00M -$23.48M
YoY Change
Total Liabilities & Shareholders Equity $64.00M $76.70M $104.1M
YoY Change -16.56% -24.09% 16.31%

Cashflow Statement

Concept 2015 Q3 2014 Q3 2013 Q4
OPERATING ACTIVITIES
Net Income -$6.431M -$7.745M -$7.589M
YoY Change -16.97% -758.59% -126.73%
Depreciation, Depletion And Amortization $250.0K $300.0K $420.0K
YoY Change -16.67% -30.23% 23.53%
Cash From Operating Activities -$10.72M -$11.16M -$9.610M
YoY Change -3.94% 50.4% -292.97%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K -$40.00K -$50.00K
YoY Change 25.0% 300.0% -66.67%
Acquisitions
YoY Change
Other Investing Activities $13.59M $11.24M $12.81M
YoY Change 20.91% 100.71% -541.72%
Cash From Investing Activities $13.53M $11.20M $12.77M
YoY Change 20.8% 100.72% -517.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 340.0K 4.740M 120.0K
YoY Change -92.83% 233.8% -73.91%
NET CHANGE
Cash From Operating Activities -10.72M -11.16M -9.610M
Cash From Investing Activities 13.53M 11.20M 12.77M
Cash From Financing Activities 340.0K 4.740M 120.0K
Net Change In Cash 3.150M 4.780M 3.280M
YoY Change -34.1% -1238.1% 37.82%
FREE CASH FLOW
Cash From Operating Activities -$10.72M -$11.16M -$9.610M
Capital Expenditures -$50.00K -$40.00K -$50.00K
Free Cash Flow -$10.67M -$11.12M -$9.560M
YoY Change -4.05% 50.07% -286.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6416000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-6431000
us-gaap Share Based Compensation
ShareBasedCompensation
4792000
us-gaap Share Based Compensation
ShareBasedCompensation
3932000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7947000
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-202000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-202000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-7745000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7758000
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71382000
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59845000
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71382000
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61494000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
753000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1034000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-659000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
7781000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-14000
thld Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-3216000
thld Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-13631000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1123000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1638000
thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
-100000
thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
-3302000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
22000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
90000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11041000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-30427000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
109000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
46622000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
43275000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1997000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
51634000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
46715000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
6900000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28845000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
28845000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5318000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7279000
CY2014Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1649000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8300000
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8300000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28100000
CY2015Q1 thld Warrants Initial Exercise Price
WarrantsInitialExercisePrice
10.86
CY2014Q3 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-1558000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6431000
CY2015Q1 thld Warrant Maximum Adjusted Exercise Price
WarrantMaximumAdjustedExercisePrice
10.86
CY2014Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
thld Weighted Average Maturity For Available For Sale Securities
WeightedAverageMaturityForAvailableForSaleSecurities
P3M9D
CY2015Q1 thld Warrant Minimum Adjusted Exercise Price
WarrantMinimumAdjustedExercisePrice
3.62
CY2015Q1 thld Warrant Term
WarrantTerm
P5Y
CY2015Q1 thld Warrants Twenty Day Vwap Exceeds
WarrantsTwentyDayVWAPExceeds
18.00
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3961000
us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
14692000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
17000
CY2015Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
19295000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1476000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1198000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4792000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3932000
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12000000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2015Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
32000
CY2014Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
17000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
100000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8168942
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2278500
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
68759
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
91218
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10287465
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10215027
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6481218
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.69
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.38
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.98
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.53
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.84
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.84
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.50
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M10D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M21D
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8850855
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
8842746
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8345365
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
CY2015Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
56414000
CY2014Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
58577000
CY2015Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
42708000
CY2015Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2015Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
42705000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
50222000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
17000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
50209000
CY2015Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
191000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
768000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
260000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1219000

Files In Submission

Name View Source Status
0001564590-15-009044-index-headers.html Edgar Link pending
0001564590-15-009044-index.html Edgar Link pending
0001564590-15-009044.txt Edgar Link pending
0001564590-15-009044-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
thld-10q_20150930.htm Edgar Link pending
thld-20150930.xml Edgar Link completed
thld-20150930.xsd Edgar Link pending
thld-20150930_cal.xml Edgar Link unprocessable
thld-20150930_def.xml Edgar Link unprocessable
thld-20150930_lab.xml Edgar Link unprocessable
thld-20150930_pre.xml Edgar Link unprocessable
thld-ex101_484.htm Edgar Link pending
thld-ex311_6.htm Edgar Link pending
thld-ex312_8.htm Edgar Link pending
thld-ex321_10.htm Edgar Link pending
thld-ex322_7.htm Edgar Link pending